|
During a procedure, a farawave and versacross connect transseptal access product were selected for use.During the procedure, a total of 97 ablation applications were delivered, including 82 lesions to the pulmonary veins and posterior wall and 15 lesions to the cavotricuspid isthmus.Due to the high lesion count, the physician administered 1.5 l of intravenous fluids intraoperatively.No malfunctions were reported at this time.Following the procedure, the patient developed hematuria, and the physician indicated that the high number of ablation applications may have contributed to hemolysis and the subsequent hematuria.As a result, the patient was admitted to the hospital for overnight observation and received additional intravenous fluids.No diagnostic test results related to hemolysis were available.The hematuria resolved after treatment, and the patient was discharged the following day with no additional complications reported.
|
|
D2a: common device name: percutaneous cardiac ablation catheter for treatment of atrial fibrillation with irreversible electroporation; reported here as the common device name exceeded the character limit for designated field.Detailed product information was not provided to bsc.We completed a good faith effort to obtain the information.It was confirmed that lot number is unknown.Therefore, bsc is unable to provide the complete unique identifier (udi) # and other product specific information.If additional details become available, a supplemental report will be submitted.
|